Increased production capacity and market presence expected to drive competitive position and organic growth; follows previous investments in Ireland and China Wilmington, Del., April 01, 2025 (GLOBE NEWSWIRE) -- Ashland has completed a 10-million-dollar expansion of its pharmaceutical manufacturing plant in Cabreúva, Brazil and will celebrate the occasion with a ribbon-cutting ceremony on April 4, 2025. The investment significantly expands Ashland's pharmaceutical footprint in the region and capabilities to ...

Core Insights - Ashland Inc. is hosting an Innovation Day on May 29, 2025, to showcase its enhanced technology platforms and commercial opportunities [1][2] - The event will include presentations from Ashland's executive and senior technology team, followed by a Q&A session and a lab tour for in-person attendees [2][3] Event Details - The Innovation Day will take place at Ashland's Bridgewater, New Jersey facility, starting at 9:00 a.m. ET and concluding around 2:00 p.m. ET [3] - Registration is required for attendance, with options for both in-person and live webcast participation [1][3] - In-person attendees will have the opportunity to engage with Ashland's leadership and experience a lab tour showcasing applications in Life Sciences, Personal Care, and Specialty Additives [3] Company Overview - Ashland Inc. is a global company specializing in additives and specialty ingredients, serving various markets including construction, energy, food and beverage, and pharmaceuticals [4] - The company employs approximately 3,200 professionals, including scientists and engineers, dedicated to developing innovative solutions for complex problems [4]

Ashland Inc. (ASH) recently announced the completion of its Avoca business divestment to Mane effective March 14, 2025. The terms of this transaction were not disclosed.ASH’s Avoca business provides sclareolide, a fragrance fixative, and a range of contract manufacturing capabilities from two production facilities in North Carolina and Wisconsin. Avoca was the last business line under Ashland remaining from the previous acquisition of Pharmachem. Avoca, being a strong player in this space, has a dedicated t ...

Wilmington, Del., March 17, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) announced today that it has completed the sale of its Avoca business to Mane effective March 14, 2025. Financial terms of the transaction were not disclosed. The Avoca business supplies sclareolide, a fragrance fixative, and a range of contract manufacturing capabilities from two production facilities in North Carolina and Wisconsin.  The Avoca business line represents the last entity from Ashland's previous acquisition of Pharmach ...

Ashland (NYSE: ASH ) is generating attractive free cash flow and holding its FCF margin in the midst of an atrocious downcycle for chemicals companies, and it is well positioned to hit its 2027 target of $600mm EBITDA and 50% FCF conversionAfter graduated from MIT with a PhD degree in 2017, with a dissertation that focuses on leveraging data analytics to understand and dissect the commodities structural market, I started managing third party money at a $1+ billion hedge fund under a profit-sharing agreement ...

Company Overview - TScan Therapeutics is a biotechnology company focused on developing engineered T cell receptor therapies aimed at treating various forms of cancer [1] Product Development - The company's initial product is an HA-2-directed T cell therapy, which represents their first attempt to enter the cancer treatment market [1] Expertise and Mission - The company emphasizes the importance of understanding the science behind its business and aims to educate investors about the complexities of the biotech industry [1]

Core Insights - Ashland Global Holdings Inc. (ASH) reported adjusted earnings of 28 cents per share for Q1 fiscal 2025, a decrease from 45 cents in the same quarter last year, but exceeding the Zacks Consensus Estimate of 20 cents [1] - Total sales fell 14.4% year over year to $405 million, missing the Zacks Consensus Estimate of $433.2 million [2] Segment Highlights - **Life Sciences**: Sales dropped 33% year over year to $134 million, below the Zacks Consensus Estimate of $160.8 million, attributed to portfolio optimization and lower pharmaceutical sales due to weak market demand and inventory control actions, particularly in EMEA [3] - **Personal Care**: Sales increased by 3.9% year over year to $134 million, aligning with the Zacks Consensus Estimate of $133.9 million, driven by higher sales volumes in skin care, hair care, and biofunctionals [4] - **Specialty Additives**: Sales decreased by 5.7% year over year to $115 million, in line with the Zacks Consensus Estimate of $115.3 million, primarily due to portfolio optimization actions that reduced sales by approximately $7 million [5] - **Intermediates**: Sales remained stable year over year at $33 million, slightly below the Zacks Consensus Estimate of $34.3 million [6] Financial Performance - Operating activities consumed $30 million in cash flows during the first quarter, with free cash flow reported at negative $26 million compared to positive $66 million in the previous year, influenced by inventory corrections and reduced variable compensation payouts [7] - For the full fiscal year, sales are projected to be between $1.90 billion and $2.05 billion, with adjusted EBITDA expected in the range of $430 million to $470 million [8] Stock Performance - Ashland's shares have declined by 31.5% over the past year, compared to a 15.5% decline in the industry [9]

earnings conference call first quarter fiscal 2025 January 29, 2025 Forward-Looking Statements This presentation contains for ward-looking storements within the meaning of Section 274 of the Securities Ach of 1933, as amended and Section 21E of the Securities Exchang 994, as amended. Ashland has identified some of these forward-looking statements with words such as "anticipates," "expects," estimates," "is likely," "predicts", fprojects, "forecasts," "dajectives," "mory" "will," "will," "will," "plans" and ...

Financial Performance - Sales for the three months ended December 31, 2024, were $405 million, a decrease of 14.4% from $473 million in the same period of 2023[7]. - Gross profit increased to $111 million, up 13.3% from $98 million year-over-year[7]. - Operating loss for the quarter was $179 million, compared to an operating loss of $18 million in the prior year[7]. - Net income loss was $165 million, a significant decline from a net income of $26 million in the same quarter of 2023[7]. - Basic earnings per share from continuing operations was $(3.51), compared to $0.54 in the same period last year[7]. - Adjusted EBITDA for the three months ended December 31, 2024, was $61 million, down from $70 million in the same period of 2023, reflecting a $9 million decrease primarily due to portfolio optimization actions[154]. - For the three months ended December 31, 2024, Ashland reported a net loss of $165 million compared to a net income of $26 million in the same period of 2023[188]. - The diluted EPS from continuing operations was $(3.51) for the three months ended December 31, 2024, compared to $0.54 in the prior year[191]. Asset and Liability Management - Total assets decreased to $5,231 million from $5,645 million as of September 30, 2024[8]. - Cash and cash equivalents at the end of the period were $219 million, down from $300 million at the beginning of the period[10]. - As of December 31, 2024, Ashland's long-term debt was $1,313 million, a decrease from $1,349 million as of September 30, 2024[54]. - The total allowance for credit losses was $1 million at both December 31, 2024, and September 30, 2024[97]. - Ashland's restricted investments totaled $350 million as of December 31, 2024, with $73 million classified within other current assets[41]. Impairments and Restructuring - An impairment charge of $183 million was recorded related to the Avoca business, impacting the loss on acquisitions and divestitures[22]. - The company initiated a restructuring plan in fiscal 2025 to offset the impact from the sale of the Nutraceuticals business, which was completed in fiscal 2024[29]. - The company reported an impairment charge of $183 million related to the Avoca business for the three months ended December 31, 2024[133]. - Ashland initiated a $30 million restructuring plan to offset impacts from the Nutraceuticals sale, with expected realization of 50% in fiscal 2025 and 50% in fiscal 2026[143]. Segment Performance - Life Sciences segment sales decreased to $134 million from $200 million, representing a decline of 33%[132]. - Personal Care segment sales increased slightly to $134 million from $129 million, a growth of 3.9%[132]. - Specialty Additives segment sales decreased to $115 million from $122 million, a decline of 5.7%[132]. - Operating income for Life Sciences was $14 million, down from $32 million, a decrease of 56.3%[132]. - Life Sciences reported a decrease in operating income to $14 million for the three months ended December 31, 2024, down from $32 million in the same period of 2023, representing a change of $(18) million[204]. Tax and Regulatory Matters - The effective tax rate for the three months ended December 31, 2024, was 21%, influenced by jurisdictional income mix and a net $8 million from unfavorable tax discrete items[68]. - The overall effective tax rate for the three months ended December 31, 2023, was a benefit of 600%, influenced by jurisdictional income mix and net favorable tax discrete items of $24 million[70]. - As of December 31, 2024, the balance of unrecognized tax benefits was $64 million, with a decrease of $2 million related to prior years and an increase of $1 million for the current year[72]. Environmental and Legal Reserves - Total reserves for asbestos claims were $264 million as of December 31, 2024, reflecting an increase of $24 million during fiscal 2024[83]. - Ashland's asbestos-related litigation reserves are currently estimated at $264 million, with potential future costs ranging up to approximately $410 million, depending on various assumptions[99]. - The total reserves for environmental remediation decreased from $221 million at September 30, 2024, to $216 million at December 31, 2024, reflecting disbursements of $6 million and revised obligation estimates of $1 million[102][103]. Market and Operational Challenges - The company anticipates challenges due to ongoing geopolitical conflicts affecting supply chains and market conditions[134]. - Total sales for the current quarter decreased by $68 million to $405 million, driven by divestitures, lower volume, unfavorable pricing, and foreign currency exchange impacts[156]. - The decline in sales, operating income, and EBITDA was attributed to lower volume, portfolio optimization activities, divestiture of the Nutraceuticals business, unfavorable pricing, and foreign currency exchange impacts[205]. Stock and Dividends - The company has a stock repurchase program with $620 million remaining available for repurchase as of December 31, 2024, following the authorization of a new $1 billion program in June 2023[110]. - Dividends paid in the first quarter of fiscal 2025 were $0.405 per share, an increase from $0.385 per share in the first quarter of fiscal 2024[112].

Core Insights - Ashland reported revenue of $405 million for the quarter ended December 2024, a decrease of 14.4% year-over-year, and EPS of $0.28, down from $0.45 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of $433.23 million, resulting in a surprise of -6.52%, while the EPS exceeded the consensus estimate of $0.20 by 40% [1] Revenue Performance - Revenue from Intermediates was $33 million, slightly below the estimated $34.30 million, showing no change from the previous year [4] - Revenue from Specialty Additives was $115 million, slightly below the estimated $115.26 million, reflecting a decline of 5.7% year-over-year [4] - Revenue from Personal Care reached $134 million, slightly above the estimated $133.90 million, marking an increase of 3.9% compared to the previous year [4] - Revenue from Life Sciences was $134 million, significantly below the estimated $160.78 million, representing a year-over-year decline of 33% [4] Adjusted EBITDA Performance - Adjusted EBITDA for Life Sciences was $28 million, below the estimated $37.61 million [4] - Adjusted EBITDA for Intermediates was $6 million, slightly below the estimated $6.63 million [4] - Adjusted EBITDA for Specialty Additives was $13 million, exceeding the estimated $7.58 million [4] - Adjusted EBITDA for Personal Care was $30 million, surpassing the average estimate of $22.97 million [4] Stock Performance - Ashland's shares returned +0.3% over the past month, compared to a +0.8% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]